Metabolomics Market Size
The metabolomics market reached US$ 3.61 billion in 2025 and is expected to reach US$ 10.82 billion by 2035, growing with a CAGR of 12.9% during the forecast period 2026-2035.
In metabolomics, biological metabolites are identified and quantified using sophisticated analytical techniques, and information is extracted and interpreted using statistical and multivariate approaches. LC-MS/MS, GC-MS, and/or NMR are some of the complementary analytical techniques used in metabolomics to identify and quantify as many known and unidentified metabolites as possible.
Metabolomics Market Key Takeaways
- The metabolomics market reached USD 3.61 billion in 2025 and is expected to surpass USD 10.82 billion by 2035 based on CAGR-driven projections.
- Rising investment from government agencies and private research organizations continues to strengthen metabolomics infrastructure worldwide.
- North America remains the leading regional market due to strong research funding, precision medicine initiatives, and an established biotechnology ecosystem.
- Asia-Pacific is expected to record the fastest growth as healthcare investment, pharmaceutical research, and laboratory infrastructure expand.
- LC-MS technologies continue to represent a major analytical platform because of their sensitivity, selectivity, and broad applicability in biomarker discovery and metabolite profiling.
- Industry leaders are increasingly integrating AI-enabled data interpretation with advanced mass spectrometry platforms to improve research productivity and analytical accuracy.
Metabolomics Market Scope
| Metrics | Details |
| Market Size (2025) | USD 3.61 Billion |
| Market Size (2035) | USD 10.82 Billion |
| CAGR (2026-2033) | 12.90% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Segments Covered | By Product and Services, By Application, By Indication, By Region |
| Largest Regional Market | North America |
| Fastest Growing Region | Asia-Pacific |
To Get a Free Sample Click here
Metabolomics Market Dynamics
The metabolomics market growth is driven by the rising funding in research and development, rising adoption of targeted therapies, technological advancement, increasing healthcare and R&D expenditure, and rise in adoption of technology for clinical applications.
The rising funding for research and development is expected to drive the market growth
The rising funding for research and development from private and government organizations is expected to boost the market over the forecast period. For instance, the Canadian Foundation for Innovation’s Major Science Initiatives Fund has provided $8,879,183 to The Metabolomics Innovation Centre (TMIC) and $10,684,968 to GlycoNet Integrated Services (GIS), helping these centers to continue their pioneering research, including glycomics and metabolomics.
The complexity of the data will hamper the growth of the market
However, no one analytical method can be used to analyze the full metabolome due to the chemical diversity of small molecule metabolites. Therefore, there is an increased demand for physical storage, accurate and thorough analysis, and appropriate software/databases for visualization. The resulting data is also more complicated. Therefore, it is anticipated that the complexity of the data produced during life science research and the challenges associated with handling it will restrain the development of the metabolomics market.
Metabolomics Market Segment Analysis
The separation technique segment is expected to grow at the fastest CAGR during the forecast period (2026-2035)
The separation technique segment is expected to boost the market throughout the forecast. As per the article published in Novel Approaches in Drug Designing & Development in August 2021, the analytical technique of liquid chromatography is used to isolate the target analyte from the mixture. To effectively separate molecules of interest, liquid chromatography uses a liquid as the mobile phase and a solid as the stationary phase. Mass spectroscopy is performed to determine the molecular mass of the sample of interest. By measuring the sample ion's mass-to-charge ratio, the molecule's mass is ascertained. Due to its selectivity, low sample volume requirements, sensitivity, and speed, the combination of liquid chromatography and mass spectrometry (LC-MS) is a potent instrument with several applications. LC is now compatible with MS due to creative and fruitful research over the past few years on constructing a potential interface link between the two. In the preclinical development stage, LC-MS detects impurities, degradants, and metabolites. In addition, the use of LC-MS/MS for protein quantification has attracted much attention. It is employed in the detection of biomarkers.
Metabolomics Market Geographical Share
North American region holds the largest market share of the global Metabolomics market
North America dominates the metabolomics market and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market share over the forecast period (2024-2031) owing to government initiatives, growth and development research activities in metabolomics, and an increase in the adoption of metabolomics in precision medicine.
The primary aim of the Metabolomics Association of North America (MANA) is to advance the field of metabolomics, particularly in North America; to give North American researchers in metabolomics sciences and related fields the chance to network; to facilitate connections between academia and industry; to provide venues for the presentation of research findings and for workshops, and to encourage the publication of metabolomics research.
Metabolomics Market Companies and Competitive Landscape
The metabolomics market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Agilent Technologies Inc., Danaher Corporation, Waters Corporation, Bruker Corporation, Human Metabolome Technologies, Inc., Metabolon Inc., LECO Corporation, and Shimadzu Corporation, among others. The major players are adopting several growth strategies, such as treatment-type launches, acquisitions, and collaborations, contributing to the growth of the global metabolomics market.
Thermo Fisher Scientific Inc
Overview:
Thermo Fisher Scientific Inc. is an American company founded in 1956 and headquartered in the United States. It provides solutions including chromatographic separations such as GC, LC, and IC. It produces novel, stringent, and reproducible results for high-impact discoveries.
Treatment type Portfolio:
Orbitrap Exploris GC 240: Thermo Scientific Orbitrap Exploris GC 240 mass spectrometer facilitates the most difficult analytical challenges. It delivers uncompromising qualitative and quantitative information and provides the need for research laboratories for compound identification and quantitation, including discovery profiling, metabolomics, industry research, and applied quantification analyses, to gain unparalleled access to information-rich data with ease.
Metabolomics Market Recent Developments
- April 2026 – Thermo Fisher expands high-resolution metabolomics and multiomics workflow solutions
Thermo Fisher Scientific Inc. introduced advanced mass spectrometry and AI-enabled metabolomics analysis platforms designed to accelerate biomarker discovery, precision medicine, and pharmaceutical research applications. - April 2026 – Agilent advances automated metabolomics sample preparation and analytics platforms
Agilent Technologies Inc. launched upgraded chromatography and metabolomics workflow technologies supporting higher-throughput metabolite profiling and improved reproducibility in life sciences research. - March 2026 – Waters strengthens precision metabolomics and biomarker research capabilities
Waters Corporation expanded its high-performance liquid chromatography and mass spectrometry portfolio to support clinical metabolomics, drug discovery, and systems biology applications. - March 2026 – Bruker introduces AI-driven metabolomics and spatial biology technologies
Bruker Corporation strengthened its omics research portfolio with enhanced metabolomics instrumentation and AI-supported data interpretation tools targeting translational and clinical research markets. - February 2026 – Shimadzu advances metabolomics instrumentation for pharmaceutical and clinical research
Shimadzu Corporation launched next-generation LC-MS systems and metabolomics software platforms designed to improve sensitivity, speed, and data analysis accuracy in metabolite profiling workflows. - February 2026 – Metabolon expands precision metabolomics services for biopharma research
Metabolon Inc. strengthened global metabolomics service offerings with expanded biomarker discovery, clinical trial analytics, and systems biology research capabilities. - January 2026 – Human Metabolome Technologies enhances biomarker discovery and metabolite analysis services
Human Metabolome Technologies, Inc. expanded metabolite profiling and clinical research support services focused on disease diagnostics, nutrition science, and precision healthcare applications.
Strategic Impact Analysis
Increasing investment in metabolomics infrastructure is reshaping pharmaceutical research and clinical biomarker development. However, organizations must balance analytical performance with the growing complexity of metabolomic data management. Companies capable of integrating high-performance instrumentation with AI-powered software, automated workflows, and scalable bioinformatics solutions are likely to gain competitive advantages as research datasets continue expanding.
How This Report Supports Business Decisions
This report enables manufacturers, pharmaceutical companies, biotechnology firms, investors, laboratory equipment suppliers, research organizations, and corporate strategy teams to evaluate emerging commercial opportunities within the metabolomics ecosystem. It provides insights into market growth, competitive positioning, technology adoption, regional investment patterns, segmentation trends, and strategic developments influencing purchasing and investment decisions through 2035.
Target Audience
- Pharmaceutical Companies
- Biotechnology Companies
- Clinical Research Organizations
- Academic Research Institutes
- Diagnostic Laboratories
- Healthcare Providers
- Mass Spectrometry Equipment Manufacturers
- Laboratory Software Providers
- Government Research Agencies
- Contract Research Organizations
- Venture Capital Firms
- Institutional Investors
- Procurement Teams
- Corporate Strategy Teams
- Life Science Technology Companies
Conclusion
Metabolomics is becoming an increasingly important pillar of precision medicine, pharmaceutical innovation, and translational research. Continued investment in biomarker discovery, advanced analytical technologies, and integrated multiomics platforms is expected to support sustained market expansion through 2035. While data complexity and bioinformatics requirements remain operational challenges, ongoing advances in AI-enabled analytics, automation, and high-performance instrumentation are improving accessibility and research productivity. Organizations that combine scientific expertise with scalable analytical platforms and comprehensive research services will be well positioned to capitalize on growing demand across healthcare, biotechnology, and pharmaceutical industries.
